Xikui Liu, Ph.D.
Affiliations: | 2005 | State University of New York, Buffalo, Buffalo, NY, United States |
Area:
Immunology, Cell BiologyGoogle:
"Xikui Liu"Parents
Sign in to add mentorSarah L. Gaffen | grad student | 2005 | SUNY Buffalo | |
(Interleukin -17 gene regulation in T cells.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Liu X, Zawidzka EM, Li H, et al. (2019) RORγ agonists enhance the sustained antitumor activity through intrinsic Tc17 cytotoxicity and Tc1 recruitment. Cancer Immunology Research |
Hu X, Majchrzak K, Liu X, et al. (2018) In vitro priming of adoptively transferred T cells with a RORγ agonist confers durable memory and stemness in vivo. Cancer Research |
Hu X, Liu X, Li H, et al. (2018) Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Tumor selection and evaluation of renal cell and bladder cancer for inclusion in phase 2a expansion. Journal of Clinical Oncology. 36: 424-424 |
Carter L, Liu X, Li H, et al. (2018) RORγ agonist LYC-55716, a novel small molecule immunotherapy: Rationale for clinical evaluation in non-small cell lung cancer based on translational and bioinformatic evaluation. Journal of Clinical Oncology. 36: 171-171 |
Weems GA, Hu X, Liu X, et al. (2018) Lyc-55716: A novel small-molecule RORγ agonist immuno-oncology agent: Rationale for tumor selection and clinical evaluation of gastric and esophageal carcinoma in phase 2a expansion. Journal of Clinical Oncology. 36: 67-67 |
Hu X, Liu X, Li H, et al. (2018) Abstract 5566: LYC-55716, a first-in-class RORγ agonist: Rationale and preclinical data to support clinical combinations with established immunotherapies Cancer Research. 78: 5566-5566 |
Gaur P, Verma V, Nandre R, et al. (2018) Abstract 3773: RORγ agonist enhances antitumor effects of agonist anti-OX40 antibody Cancer Research. 78: 3773-3773 |
Gaur P, Verma V, Nandre R, et al. (2018) Abstract 3762: Novel RORγt agonist induces antitumor immune effect through enhancement of tumor antigen-specific CD8+ T-cell infiltration into the TME Cancer Research. 78: 3762-3762 |
Franchi L, Monteleone I, Hao LY, et al. (2017) Inhibiting Oxidative Phosphorylation In Vivo Restrains Th17 Effector Responses and Ameliorates Murine Colitis. Journal of Immunology (Baltimore, Md. : 1950) |
Hu X, Liu X, Moisan J, et al. (2016) Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity. Oncoimmunology. 5: e1254854 |